Lv4
488 积分 2025-12-16 加入
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)
3天前
已完结
Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515)
3天前
已完结
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study
4天前
已完结
Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours
5天前
已完结
Focus on kidney cancer
5天前
已完结
Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma
5天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
17天前
已完结
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
17天前
已完结
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
21天前
已完结
RETRACTED ARTICLE: The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma
23天前
已完结
皖公网安备34019202002308
